newsfilter
← Latest News
GlobeNewswire·

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company"), today announced